Empagliflozin Promotes Natriuresis in Diabetic Patients with Cirrhotic Refractory Ascites: A Proof-of-Concept Study. (PubMed, J Gastrointestin Liver Dis) - Sep 29, 2026 - "In this open-label, proof-of-concept study, empagliflozin was associated with improved short-term natriuretic indices over 10 days in diabetic patients with decompensated cirrhosis and refractory ascites, without serious adverse events. Larger, blinded, longer-term trials are warranted to confirm these preliminary findings."
Clinical • Journal • Diabetes • Fibrosis • Immunology • Metabolic Disorders • Type 2 Diabetes Mellitus
|
|
Feng Zhao; Jianru Jia; Longzhen Zhou; Rongya Shi; Wei Qin; Yuan Gao; Yunyi Gao; Zhongjie Hu
|